Globalance Footprint
of
Fights against widespread disease diabetes
Profile
Since its founding in Denmark in 1923, the company has become a global leader in diabetes pharmacy. They have 46% of the global insulin market. Key products include diabetes care medications and devices. Novo also develops and distributes anti-clotting medications and hormone therapies.
Footprint overview
Insulin is a special case. For people with type 1 diabetes and for some people with type 2 diabetes, it is an essential, life-saving medicine for which there is no alternative. It’s Novo Nordisk’s ambition that everyone who needs insulin has access to it at prices they can afford. Differential pricing strategies depending on country specific factors proof their ambition.
Footprint Score:
62 Points of 100
Footprint according to Themes
The Footprint of Novo Nordisk is determined by the following Impacts:
Economy
Society
-
Nutrition
0/0
-
Health
40
40/60
-
Education and Knowledge
0/0
Environment
-
Biodiversity and Land
11
11/20
-
Resources and Climate
0/0
-
Water
0/0
adverse MSCI World43
Balanced 100
positive
Keys:
- Colors indicate Footprint Themes
- Length of bars indicate impact contribution per theme
- Actual/Max-column compares for each theme the actual scores to the maximum achievable in this sector or asset class. 0/0 stands for a theme not assessed.
The most important themes
The following themes contribute the most to the positive footprint of Novo Nordisk:
-
Health
- Access to affordable healthcare
- Diversity of therapies, also for rare diseases
- New business models for healthcare providers
-
Markets and Infrastructure
- Reduced corruption
- Highly developed financial markets
- Puts in place
sustainable infrastructure for energy, transport and communication
- Reduced corruption
-
Biodiversity and Land
- Preserves the variety of species in the air, soil and water
- Increases the resilience and quality of land and water resources
- Avoids, reduces anddisposes waste
- Preserves the variety of species in the air, soil and water
Did you know
Since 1990, the number of people living with type 2 diabetes has doubled. If the 393 million people living with the disease were a nation, it would be the third most populous on earth with more citizens than the United States of America. The world is rapidly urbanising and two thirds of people living with diabetes reside in cities – a number that rises each day. The way urban areas are designed, built and run is changing the way we live and, in some cases, increasing our vulnerability to diabetes. That’s why Novo Nordisk initiated “Cities Changing Diabetes” in partnership with University College London and Steno Diabetes Center Copenhagen and 100 partners. 19 cities already joined.
Selected Footprint Facts
In 2018, 5 million people with diabetes were treated with Novo’s human insulin at a maximum of 4 USD per 10ml vial. As a result, people can be treated with insulin for on average USD 0.12 per day.
In 2018, Novo Nordisk set an ambition to have zero negative environmental impact. To get there, a new environmental strategy was adopted that addresses risks across the entire value chain, including climate change, water and resource scarcity, pollution and plastic waste.
Novo Nordisk had three product recalls from the market in 2018. None of these recalls were critical. Product safety is high.
Source: Novo Nordisk
Lars Fruergaard Jørgensen CEOThe number of people with diabetes is growing at an alarming rate. The latest estimates are that by 2035 close to 600 million people will have diabetes and at some point most of them will require medical treatment.
Source: Novo Nordisk
Revenue By Region
- North America 51%
- Europe 22%
- Asia-Pacific 20%
- Remaining world 17%
Revenue By Business
- Biopharmaceuticals 20%
- Diabetes Care 80%
Source: Novo Nordisk